5-Fluorouracil in hepatocellular carcinoma. Report of twenty-one cases
β Scribed by John S. Link; Joseph R. Bateman; Warren S. Paroly; Walter J. Durkin; Robert L. Peters
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- English
- Weight
- 327 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a ramdomized treatment schedule. Twenty-one patients were evaluable for response and toxicity. The two groups were comparable in distribution of pretreatment characteristics. There were no objective responses in either group. This is the largest reported group of patients with hepatocellular carcinoma treated with 5-Fluorouracil. Toxicity occurred in 46% of patients treated, but was tolerable. In contrast to previous reports,l1.l3 we have found that weekly 5-Fluorouracil given orally or intravenously is not of significant value in the treatment of hepatocellular carcinoma.
π SIMILAR VOLUMES
BCL10 was found to have truncated mutations at a high frequency in MALT (mucosa-associated lymphoid tissue) B cell lymphomas. We examined the mutations of BCL10 gene in human primary liver cancer using non-isotopic PCR-SSCP. Three exons were examined in both cancer and non-HCC adjacent liver tissues
## BACKGROUND. There have been no reports of creatine phosphokinase (CKJ elevation during levamisole administration. There is only one prior report of CK elevation of noncardiac origin associated with 5-fluorouracil. ## METHODS. A 41-year-old man was diagnosed with Stage B2 colon carcinoma and
In adults, the term specific pulmonary renal syndrome describes disorders with pulmonary and glomerular manifestations and includes Wegener's granulomatosis, Goodpasture disease, and systemic lupus erythematosus. Nonspecific pulmonary renal syndrome refers to either pulmonary disease complicating gl
## Background: Neutropenic enterocolitis is observed in approximately 25% of patients with acute leukemia, but has been reported rarely in patients with solid tumors. if treatment is not initiated promptly, the mortality is high. the incidence of this disease is rising in patients with hematologic
Recent in vitro and animal tumor studies suggest that sequential methotrexate (MTX) and 5-fluorouracil (5-FU) may be much more tumoricidal than either drug when used alone or in conventional combinations. Seventeen evaluable female patients with advanced carcinoma of the breast were treated with MTX